Effecy and Safety of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors on Atrial Fibrillation

Effecy and Safety of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors on Atrial Fibrillation - Effecy and Safety of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors on Atrial Fibrillation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024326

Enrollment

Registered

2016-10-07

Start date

2017-03-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibrillation

Interventions

In intervention group, patients are treated with SGLT2 inhibitors for 2-6 weeks before the catheter ablation. In control group, patients are treated with DPP4 inhibitor for 2-6 weeks before the cathe

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes mellitus (6.5< HbA1c <10%) patients with non-valvular AF who undergo the catheter ablation. All patients are treated with oral anti-coagulants.

Exclusion criteria

Exclusion criteria: 1. Prior history of stroke / transient ischemic attack within 3-month 2. Valvular AF 3. Prior history of cardiac surgery 4. Chronic kidney disease (eGFR <30)

Design outcomes

Primary

Measure	Time frame
Primary outcome is recurrence of atrial fibrillation at 12-month after catheter ablation.	—

Secondary

Measure	Time frame
1)Recurrence of atrial fibrillation at 1, 3, 6, and 9-month after catheter ablation 2)Estimated glomerular filtration and creatinine (at 3 and 12-month after catheter ablation) 3)Quolity of life (at 1, 3, 6, and 12-month after catheter ablation) 4)Body weight index (at 1, 3, 6, 9, and 12-month after catheter ablation) 5)Body mass index (at 1, 3, 6, 9, and 12-month after catheter ablation) 6)waist circumference (at 1, 3, 6, 9, and 12-month after catheter ablation) 7)Heart rate at rest (at 1, 3, 6, 9, and 12-month after catheter ablation) 8)Blood pressure (at 1, 3, 6, 9, and 12-month after catheter ablation) 9)The following factors (at 3 and 12-month after catheter ablation) triglyceride, LDL-cholesterol, HDL-cholesterol, fatty acids, Hb, Hct, Cystatin C, CA-125, blood ketone body, renin, aldosterone, Brain natriuretic peptide, Atrial natriuretic peptide, HbA1c, IRI, glycoalbumin, urinary albumin 10)The following echocardiographic findings (at 3 and 12-month after catheter ablation) Left atrial functions Left atrial diameter, Left atrial volume E/e` ratio Left ventricular ejection fraction Velocity time integral Spontaneous echo contrast Left atrial appendage flow velocity 12)Left atrial pressure and low voltage area (during catheter ablation) 13)Cardio Thoracic Ratio (at 12-month after catheter ablation)	—

Measure

Time frame

1)Recurrence of atrial fibrillation at 1, 3, 6, and 9-month after catheter ablation 2)Estimated glomerular filtration and creatinine (at 3 and 12-month after catheter ablation) 3)Quolity of life (at 1, 3, 6, and 12-month after catheter ablation) 4)Body weight index (at 1, 3, 6, 9, and 12-month after catheter ablation) 5)Body mass index (at 1, 3, 6, 9, and 12-month after catheter ablation) 6)waist circumference (at 1, 3, 6, 9, and 12-month after catheter ablation) 7)Heart rate at rest (at 1, 3, 6, 9, and 12-month after catheter ablation) 8)Blood pressure (at 1, 3, 6, 9, and 12-month after catheter ablation) 9)The following factors (at 3 and 12-month after catheter ablation) triglyceride, LDL-cholesterol, HDL-cholesterol, fatty acids, Hb, Hct, Cystatin C, CA-125, blood ketone body, renin, aldosterone, Brain natriuretic peptide, Atrial natriuretic peptide, HbA1c, IRI, glycoalbumin, urinary albumin 10)The following echocardiographic findings (at 3 and 12-month after catheter ablation) Left atrial functions Left atrial diameter, Left atrial volume E/e` ratio Left ventricular ejection fraction Velocity time integral Spontaneous echo contrast Left atrial appendage flow velocity 12)Left atrial pressure and low voltage area (during catheter ablation) 13)Cardio Thoracic Ratio (at 12-month after catheter ablation)

—

Countries

Japan

Contacts

Public ContactHideyuki Kishima

Hyogo collage of medicine Department of internal medicine, cardiovascular division

kishima@hyo-med.ac.jp0798-45-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026